Science
PopVax has dosed the first participants in a Phase I trial of PVX-001, a broadly-protective Covid-19 vaccine candidate that will be released open-source when the study ends.
Loading…
Search
No phones and 1 story for “PopVax”
Science
PopVax has dosed the first participants in a Phase I trial of PVX-001, a broadly-protective Covid-19 vaccine candidate that will be released open-source when the study ends.